Questions around rehab safety, overdose risk and withdrawal have flared again after Presley Gerber’s death at 27. The case has pushed attention back onto a hard truth about addiction treatment: even in a residential setting, danger does not disappear, and families often learn that too late.
Gerber, the son of Cindy Crawford and Rande Gerber, died at a California rehabilitation facility, according to medical examiner records. His family asked for privacy as the details remained unsettled, while officials said an autopsy had been completed and the cause of death was still pending further testing.
That uncertainty matters because a death in treatment can point in several different directions. It may involve a medical emergency, an undetected condition, a medication issue or something unrelated to drugs altogether, which is why experts warn against jumping to conclusions before the full report is finished.
One big misconception is that rehab automatically makes someone safe. Treatment can reduce risk, but it cannot erase the fragile state many patients are already in when they arrive, especially if they are dealing with a long history of substance use, other health problems or mental health struggles at the same time.
Experts say withdrawal is one of the most dangerous parts of recovery for some patients. Alcohol and benzodiazepines such as Xanax or Valium can be especially risky when a person stops using them without medical supervision, while opioid withdrawal is usually miserable but not typically fatal on its own.
The bigger opioid danger can show up after detox is over. A person’s tolerance drops fast, and if relapse happens, the same amount that was previously used can become far more dangerous, even deadly, because the body is no longer prepared for it.
That is one reason treatment programs have to be more than a locked building with a calming brochure. Good facilities need trained medical staff, clear withdrawal protocols, medication oversight and emergency response plans, because addiction recovery can turn on medical details that are easy to miss.
Gerber had also spoken publicly about substance use and mental health, which added another layer to the public reaction. In the weeks after his death, attention turned to the kinds of therapies sometimes marketed as cutting-edge solutions, including ibogaine, ketamine and ayahuasca, all of which come with uneven evidence and major regulatory questions.
Ibogaine in particular has drawn interest as a possible treatment for opioid use disorder, especially outside the United States. But it is not FDA-approved for any medical use in the U.S., and experts say the safety picture is still murky, with little room for certainty and plenty of room for hype.
Ketamine sits in a strange middle ground. It is approved as an anesthetic, and some clinicians use it off-label in mental health care, but it is not approved as a psychiatric treatment, which makes the booming interest around psychedelic-style therapies feel a lot bigger than the evidence behind them.
That tension is part of what leaves families vulnerable. When addiction gets severe, people are often desperate for anything that sounds promising, and that desperation can make weak oversight or questionable promises look more credible than they really are.
Families thinking about treatment are urged to look beyond the sales pitch and check the basics. A licensed program with qualified professionals, solid medical supervision and a real reputation for safety matters far more than glossy marketing or dramatic success stories.
Carefully vetting a facility can also mean asking whether it can handle emergencies, how it manages medications and whether it has real experience with withdrawal complications. In a field where mistakes can cost a life, the strongest warning signs are often the ones that show up long before admission ever happens.
